Skip to main content

Management Team

Since our founding in 2009, Biogennix has been dedicated to developing advanced osteobiologic solutions for spine, foot and ankle, and general orthopedic surgery. Our leadership team is comprised of experts in bone graft science and includes pioneers in the field of advanced synthetic bone graft technology.

Our mission is to meet the needs of all customers – surgeons, hospitals, and our distributor partners – by introducing technologies that keep you a step ahead.

Biogennix develops, manufactures, and distributes our portfolio of advanced bone graft solutions out of our Irvine, CA facilities.

Chris MacDuff headshot

Chris MacDuff

Chief Executive Officer

Chris brings over two decades of diverse sales and marketing management experience to Biogennix. He has spent the last 18 years in the medical device industry, 15 years of which were spent as a successful spine device distributor for Orange County, CA. Chris began his medical device career in marketing at Interpore Cross International, then transitioned into sales management. He later founded Shoreline Surgical Inc., which represented several prominent spine and orthobiologic product lines. Prior to his spine device career, Chris worked for Four Seasons Hotels & Resorts in sales and marketing.  Chris has a B.A. from the University of Rhode Island in Business Administration and Communications.

Edwin Clayton Shors

Edwin Clayton Shors, Ph.D.


Dr. Shors has a track record of more than 30 years creating unique implantable medical devices for regenerative medicine. He has developed and commercialized synthetic bone graft substitutes, autogenous growth factors and allografts for bone reconstruction, as well as metallic orthopedic and dental implants. Prior to co-founding Biogennix, he was co-founder of Interpore International, which was acquired by Biomet in 2004 for $280 million. From 1978 to 2004, he served in a variety of senior management positions at Interpore International; including President, Chief Technology Officer and Vice President for research and development. Dr. Shors is also President of EC Shors Biomedical Consulting, Inc., which assists device companies with implants for regenerative medicine. Dr. Shors has a Ph.D. degree in Physiology and Biophysics from the University of Southern California.

MBorden headshot

Mark Borden, Ph.D.

Chief Technology Officer

Mark Borden, Ph.D. has over 27 years of biomaterial and orthobiologic R&D experience, and over 20 years of corporate leadership. Prior to joining Biogennix, Dr. Borden was the founder and CEO of Synergy Biomedical, a bone graft company focused on bioactive glass solutions for orthopedic and spine surgery. He has also held management positions with Globus Medical, Biomet, and Interpore Cross. Dr. Borden has significant experience in bringing medical device concepts to market and broad operational experience in quality, manufacturing, and regulatory affairs. Dr. Borden also holds patents for a variety of innovative medical devices, many of which remain on the market today. Dr. Borden holds a Ph.D. in Biomedical Engineering from Drexel University.